Literature DB >> 7806292

Peptide motifs of HLA-B58, B60, B61, and B62 molecules.

K Falk1, O Rötzschke, M Takiguchi, V Gnau, S Stevanović, G Jung, H G Rammensee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7806292     DOI： 10.1007/bf00182333

Source DB:  PubMed          Journal:  Immunogenetics        ISSN： 0093-7711            Impact factor:   2.846


× No keyword cloud information.
  14 in total

1.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry.

Authors:  D F Hunt; R A Henderson; J Shabanowitz; K Sakaguchi; H Michel; N Sevilir; A L Cox; E Appella; V H Engelhard
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

2.  Identification of self peptides bound to purified HLA-B27.

Authors:  T S Jardetzky; W S Lane; R A Robinson; D R Madden; D C Wiley
Journal:  Nature       Date:  1991-09-26       Impact factor: 49.962

3.  Structural analysis of HLA-B40 epitopes.

Authors:  G Kawaguchi; N Kato; K Kashiwase; S Karaki; T Kohsaka; T Akaza; K Kano; M Takiguchi
Journal:  Hum Immunol       Date:  1993-03       Impact factor: 2.850

4.  Endogenous peptides with distinct amino acid anchor residue motifs bind to HLA-A1 and HLA-B8.

Authors:  M DiBrino; K C Parker; J Shiloach; R V Turner; T Tsuchida; M Garfield; W E Biddison; J E Coligan
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

5.  The complete primary structure of HLA-Bw58.

Authors:  J P Ways; H L Coppin; P Parham
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

6.  Allelic variation in HLA-B and HLA-C sequences and the evolution of the HLA-B alleles.

Authors:  H Pohla; W Kuon; P Tabaczewski; C Doerner; E H Weiss
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

7.  Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behćet's disease.

Authors:  K Falk; O Rötzschke; M Takiguchi; V Gnau; S Stevanović; G Jung; H G Rammensee
Journal:  Int Immunol       Date:  1995-02       Impact factor: 4.823

8.  Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs.

Authors:  O Rötzschke; K Falk; S Stevanović; V Gnau; G Jung; H G Rammensee
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

9.  Comparison of the P2 specificity pocket in three human histocompatibility antigens: HLA-A*6801, HLA-A*0201, and HLA-B*2705.

Authors:  H C Guo; D R Madden; M L Silver; T S Jardetzky; J C Gorga; J L Strominger; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

10.  Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules.

Authors:  K Falk; O Rötzschke; M Takiguchi; B Grahovac; V Gnau; S Stevanović; G Jung; H G Rammensee
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846
View more
  20 in total

1.  Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires.

Authors:  John Sidney; Scott Southwood; Alessandro Sette
Journal:  Immunogenetics       Date:  2005-07-08       Impact factor: 2.846

2.  The peptide-binding specificity of HLA-A*3001 demonstrates membership of the HLA-A3 supertype.

Authors:  Kasper Lamberth; Gustav Røder; Mikkel Harndahl; Morten Nielsen; Claus Lundegaard; Claus Schafer-Nielsen; Ole Lund; Soren Buus
Journal:  Immunogenetics       Date:  2008-09-04       Impact factor: 2.846

3.  Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes.

Authors:  Hayato Murakoshi; Tomohiro Akahoshi; Madoka Koyanagi; Takayuki Chikata; Takuya Naruto; Rie Maruyama; Yoshiko Tamura; Naoki Ishizuka; Hiroyuki Gatanaga; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

4.  The Behçet's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing.

Authors:  Pablo Guasp; Eilon Barnea; M Francisca González-Escribano; Anaïs Jiménez-Reinoso; José R Regueiro; Arie Admon; José A López de Castro
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

Review 5.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay.

Authors:  M A Altfeld; A Trocha; R L Eldridge; E S Rosenberg; M N Phillips; M M Addo; R P Sekaly; S A Kalams; S A Burchett; K McIntosh; B D Walker; P J Goulder
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades.

Authors:  A Bertoletti; F Cham; S McAdam; T Rostron; S Rowland-Jones; S Sabally; T Corrah; K Ariyoshi; H Whittle
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design.

Authors:  V Novitsky; N Rybak; M F McLane; P Gilbert; P Chigwedere; I Klein; S Gaolekwe; S Y Chang; T Peter; I Thior; T Ndung'u; F Vannberg; B T Foley; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

9.  T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.

Authors:  Melissa J Rist; Michelle A Neller; Jacqueline M Burrows; Scott R Burrows
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

10.  Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.

Authors:  Manuel Albanese; Takanobu Tagawa; Mickaël Bouvet; Liridona Maliqi; Dominik Lutter; Jonathan Hoser; Maximilian Hastreiter; Mitch Hayes; Bill Sugden; Larissa Martin; Andreas Moosmann; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.